André Choulika does not mince words. The Cellectis CEO is an outspoken champion of all things related to the company he founded 15 years ago.
Cardio3 Biosciences is set to become the latest European biotech to pitch up on Wall Street in search of cash from public investors. And with a clinical-phase CAR-T asset in its pipeline, the Belgian biotech stands a chance of tapping into investor enthusiasm for the red-hot niche.
Juno Therapeutics quickly built a reputation as one of the hottest biotechs in the world, raising hundreds of millions of dollars inside a year and capping it with a go-go IPO for its cancer drug pipeline that helped inspire a surge for the sector. And now that the newly public biotech has filed its first 10-K, Juno can feel the backlash as it outlines just how fast it can spend that huge cache of cash, missing a consensus estimate on projected losses by a market mile.
PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.
Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in a trial update that 12 of 13 evaluable patients with advanced B cell malignancies demonstrated a complete or partial response after being treated with its chimeric antigen receptor (CAR) T cell therapy.
Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.
Immunocore has struck another cancer R&D pact with one of the world's top drugmakers, signing a deal with Eli Lilly that'll both bring in short-term revenue and help the biotech build value in its proprietary pipeline.
Pfizer wants in on CAR-T technology, the latest much-celebrated trend in cancer R&D, striking a deal with France's Cellectis to get its hands on some tailored immunotherapies with the promise of billions in future payments.
GlaxoSmithKline's oncology division is retooling and adding a new focus on the emerging field of T-cell engineering in immuno-oncology. And in the process the pharma giant is sending a clear message that it still sees a bright future for itself in cancer drug research.
I'll be hosting a Twitter chat on Thursday afternoon--3:30 pm EST--with Dr. David Porter, one of the top investigators on the CAR-T team at the University of Pennsylvania.